Literature DB >> 20160479

Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A.

Kathryn T Bieging1, Michelle Swanson-Mungerson, Alexandra C Amick, Richard Longnecker.   

Abstract

Burkitt's lymphoma (BL) is characterized by translocation of the MYC gene to an immunoglobulin locus. Transgenic mouse models have been used to study the molecular changes that are necessary to bypass tumor suppression in the presence of translocated MYC. Inactivation of the p53 pathway is a major step to tumor formation in mouse models that is also seen in human disease. Human BL is often highly associated with Epstein-Barr virus (EBV). The EBV latency protein latent membrane protein 2A (LMP2A) is known to promote B cell survival by affecting levels of pro-survival factors. Using LMP2A transgenic mouse models, we have identified a novel mechanism that permits lymphomagenesis in the presence of an intact p53 pathway. This work uncovers a contribution of EBV to molecular events that have documented importance in BL pathogenesis, and may underlie the poorly understood link between EBV and BL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160479      PMCID: PMC2855765          DOI: 10.4161/cc.9.5.10840

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  90 in total

Review 1.  P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance.

Authors:  E W Newcomb
Journal:  Leuk Lymphoma       Date:  1995-04

2.  Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases.

Authors:  C L Miller; A L Burkhardt; J H Lee; B Stealey; R Longnecker; J B Bolen; E Kieff
Journal:  Immunity       Date:  1995-02       Impact factor: 31.745

3.  Host ethnicity influences non-Hodgkin's lymphoma subtype frequency and Epstein-Barr virus association rate: the experience of a multi-ethnic patient population in Malaysia.

Authors:  S C Peh
Journal:  Histopathology       Date:  2001-05       Impact factor: 5.087

4.  Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines.

Authors:  B C Schaefer; J L Strominger; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

5.  Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases.

Authors:  C Preudhomme; I Dervite; E Wattel; M Vanrumbeke; M Flactif; J L Lai; B Hecquet; M C Coppin; B Nelken; B Gosselin
Journal:  J Clin Oncol       Date:  1995-04       Impact factor: 44.544

6.  TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains.

Authors:  A L Børresen; T I Andersen; J E Eyfjörd; R S Cornelis; S Thorlacius; A Borg; U Johansson; C Theillet; S Scherneck; S Hartman
Journal:  Genes Chromosomes Cancer       Date:  1995-09       Impact factor: 5.006

7.  The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family.

Authors:  G Mosialos; M Birkenbach; R Yalamanchili; T VanArsdale; C Ware; E Kieff
Journal:  Cell       Date:  1995-02-10       Impact factor: 41.582

8.  Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.

Authors:  G Niedobitek; A Agathanggelou; M Rowe; E L Jones; D B Jones; P Turyaguma; J Oryema; D H Wright; L S Young
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

9.  The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt's lymphoma from Egypt: epidemiologic correlations.

Authors:  N Anwar; D W Kingma; A R Bloch; M Mourad; M Raffeld; J Franklin; I Magrath; N el Bolkainy; E S Jaffe
Journal:  Cancer       Date:  1995-10-01       Impact factor: 6.860

10.  Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module.

Authors:  N Engels; M Merchant; R Pappu; A C Chan; R Longnecker; J Wienands
Journal:  J Exp Med       Date:  2001-08-06       Impact factor: 14.307

View more
  18 in total

1.  Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.

Authors:  Osman Cen; Richard Longnecker
Journal:  Mol Cancer Ther       Date:  2011-01-31       Impact factor: 6.261

2.  Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.

Authors:  Kun-Yi Lai; Ya-Ching Chou; Jiun-Han Lin; Yi Liu; Kai-Min Lin; Shin-Lian Doong; Mei-Ru Chen; Te-Huei Yeh; Sue-Jane Lin; Ching-Hwa Tsai
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

3.  Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential.

Authors:  Shi-Dong Ma; Ming-Han Tsai; James C Romero-Masters; Erik A Ranheim; Shane M Huebner; Jillian A Bristol; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

4.  A shared gene expression signature in mouse models of EBV-associated and non-EBV-associated Burkitt lymphoma.

Authors:  Kathryn T Bieging; Kamonwan Fish; Subbarao Bondada; Richard Longnecker
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

5.  Investigation of the function of the putative self-association site of Epstein-Barr virus (EBV) glycoprotein 42 (gp42).

Authors:  Cynthia L Rowe; Hisae Matsuura; Theodore S Jardetzky; Richard Longnecker
Journal:  Virology       Date:  2011-05-08       Impact factor: 3.616

Review 6.  Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.

Authors:  Mariya O Krisenko; Robert L Geahlen
Journal:  Biochim Biophys Acta       Date:  2014-11-04

7.  Epstein-Barr virus Latent Membrane Protein 2A (LMP2A)-mediated changes in Fas expression and Fas-dependent apoptosis: Role of Lyn/Syk activation.

Authors:  Ryan Incrocci; Samira Hussain; Amanda Stone; Kathryn Bieging; Lauren A C Alt; Michael J Fay; Michelle Swanson-Mungerson
Journal:  Cell Immunol       Date:  2015-08-04       Impact factor: 4.868

8.  A soluble form of Epstein-Barr virus gH/gL inhibits EBV-induced membrane fusion and does not function in fusion.

Authors:  Cynthia L Rowe; Sarah A Connolly; Jia Chen; Theodore S Jardetzky; Richard Longnecker
Journal:  Virology       Date:  2012-11-29       Impact factor: 3.616

Review 9.  Epstein-Barr virus interactions with the Bcl-2 protein family and apoptosis in human tumor cells.

Authors:  Qin Fu; Chen He; Zheng-rong Mao
Journal:  J Zhejiang Univ Sci B       Date:  2013-01       Impact factor: 3.066

10.  Molecular Interactions between Two LMP2A PY Motifs of EBV and WW Domains of E3 Ubiquitin Ligase AIP4.

Authors:  Min-Duk Seo; Seung-Hyeon Seok; Ji-Hun Kim; Ji Woong Choi; Sung Jean Park; Bong-Jin Lee
Journal:  Life (Basel)       Date:  2021-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.